Nestlé S.A. (SWX:NESN) is discussing a potential sale of its peanut allergy medicine to Swiss health-care group Stallergenes Greer Ltd, people with knowledge of the matter said. Stallergenes has been holding talks with Nestlé about a possible deal for the Palforzia treatment, the people said, asking not to be identified discussing confidential information.
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
- EUR | -.--% | +0.14% | +29.68% |
2023 | Nestle Reportedly May Sell Peanut Allergy Therapy to Stallergenes | CI |
2023 | Stallergenes Greer Ltd Initiates European Paediatric Phase III Study with Staloral Birch | CI |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
92.7 CHF | +0.67% | -2.67% | 261B | ||
- EUR | -.--% | +0.14% | 0 | ||
1st Jan change | Capi. | |
---|---|---|
+29.68% | 0 | |
+5.31% | 70.44B | |
+10.97% | 8.94B | |
-16.83% | 4.75B | |
+43.48% | 4.5B | |
+3.20% | 3.85B | |
+18.82% | 2.38B | |
-21.36% | 2.34B | |
-29.67% | 2.2B | |
+8.38% | 1.96B |
- Stock Market
- Equities
- STAGR Stock
- News Stallergenes Greer
- Nestle Reportedly May Sell Peanut Allergy Therapy to Stallergenes